Trial Profile
A Phase 1, Open-label, Dose-escalation and Expansion Study of MEDI1191 Administered Intratumorally as Monotherapy and in Combination With Durvalumab in Subjects With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; MEDI 1191 (Primary)
- Indications Advanced breast cancer; Anal cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Neuroendocrine tumours; Non-small cell lung cancer; Pancreatic cancer; Sarcoma; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors AstraZeneca; MedImmune
- 30 Oct 2023 Status changed from active, no longer recruiting to completed.
- 19 Apr 2023 Updated results analysis (As of October 5, 2022) assessing safety and efficacy of Intratumoral MEDI1191 plus durvalumab of the first report of patients with deep-seated lesions in advanced solid tumors patients, presented at the 114th Annual Meeting of the American Association for Cancer Research.
- 30 Nov 2022 Planned End Date changed from 22 Sep 2027 to 28 Aug 2023.